esomeprazol sun pharma 40 mg pulver till injektions-/infusionsvätska, lösning
sun pharmaceutical industries europe b.v. - esomeprazolnatrium - pulver till injektions-/infusionsvätska, lösning - 40 mg - esomeprazolnatrium 42,5 mg aktiv substans
cilostazol eql pharma 100 mg tablett
eql pharma ab - cilostazol - tablett - 100 mg - cilostazol 100 mg aktiv substans - exkl. heparin
prednisolon eql pharma 5 mg tablett
eql pharma ab - prednisolon - tablett - 5 mg - laktosmonohydrat hjälpämne; prednisolon 5 mg aktiv substans
clindamycin eql pharma 150 mg kapsel, hård
eql pharma ab - klindamycinhydroklorid - kapsel, hård - 150 mg - klindamycinhydroklorid 162,88 mg aktiv substans; laktosmonohydrat hjälpämne
clindamycin eql pharma 300 mg kapsel, hård
eql pharma ab - klindamycinhydroklorid - kapsel, hård - 300 mg - laktosmonohydrat hjälpämne; klindamycinhydroklorid 325,8 mg aktiv substans
ribavirin teva pharma b.v.
teva b.v. - ribavirin - hepatit c, kronisk - antivirala medel för systemisk användning - ribavirin teva pharma b. is indicated in combination with other medicinal products for the treatment ofchronic hepatitis c (chc) in adults (see sections 4. 2, 4. 4 och 5. ribavirin teva pharma b. is indicated in combination with other medicinal products for the treatment ofchronic hepatitis c (chc) for paediatric patients (children 3 years of age and older and adolescents) notpreviously treated and without liver decompensation (see sections 4. 2, 4. 4 och 5.
dasatinib accordpharma
accord healthcare s.l.u. - dasatinib - precursor cell lymphoblastic leukemia-lymphoma; leukemia, myelogenous, chronic, bcr-abl positive - antineoplastiska medel - dasatinib accordpharma is indicated for the treatment of adult patients with: newly diagnosed philadelphia chromosome positive (ph+) chronic myelogenous leukaemia (cml) in the chronic phase. chronic, accelerated or blast phase cml with resistance or intolerance to prior therapy including imatinib. ph+ acute lymphoblastic leukaemia (all) and lymphoid blast cml with resistance or intolerance to prior therapy. dasatinib accordpharma is indicated for the treatment of paediatric patients with: newly diagnosed ph+ cml in chronic phase (ph+ cml-cp) or ph+ cml-cp resistant or intolerant to prior therapy including imatinib. newly diagnosed ph+ all in combination with chemotherapy.
carbamazepine essential pharma 125 mg suppositorium
essential pharma (m) ltd - karbamazepin - suppositorium - 125 mg - karbamazepin 125 mg aktiv substans - karbamazepin
carbamazepine essential pharma 250 mg suppositorium
essential pharma (m) ltd - karbamazepin - suppositorium - 250 mg - karbamazepin 250 mg aktiv substans - karbamazepin
tetracyklin rph pharma 250 mg tablett
rph pharmaceuticals ab - tetracyklinhydroklorid - tablett - 250 mg - sackaros hjälpämne; tetracyklinhydroklorid 250 mg aktiv substans; laktosmonohydrat hjälpämne - tetracyklin